{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:36:41Z","timestamp":1793947001291,"version":"4.8.0"},"reference-count":35,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T00:00:00Z","timestamp":1644796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Primary peritoneal mesothelioma (PPM) is a rare and aggressive tumor arising from the visceral and parietal peritoneum. The diagnosis and treatment of PPM are often delayed because of non-specific clinical presentation, and the prognosis is worse. The current study investigated the demographic, clinical, and pathological factors affecting patient prognosis and survival in PPM. Methods: Demographic and clinical data of 1998 patients with PPM were extracted from the Surveillance Epidemiology and End Results (SEER) database (1975\u20132016). The chi-square test, paired t-test, and multivariate analysis were used to analyze the data. Results: The majority of PPM patients were male (56.2%, p &lt; 0.005) and Caucasian (90.4%, p &lt; 0.005, with a mean age of diagnosis was 69 \u00b1 13 years. The grading, histological, and tumor size information were classified as \u201cUnknown\u201d in most of the cases, but when available, poorly differentiated tumors (8.7%), malignant mesothelioma, not otherwise specified (63.4%) and tumors &gt; 4 cm in size (8%), respectively, were most common, p &lt; 0.005. Chemotherapy was administered to 50.6% of patients, followed by resection (29.2%) and radiation (1.5%), p &lt; 0.001. The cohort of PPM had a five-year overall survival of 20.3% (\u00b11.1), compared to 43.5% (\u00b15.9), 25.9% (\u00b1 8.4), and 18.7% (\u00b11.6) for those with surgery, radiation, or chemotherapy alone, respectively. Poor differentiation (OR = 4.2, CI = 3.3\u20134.9), tumor size &gt; 4 cm (OR = 3.9, CI = 3.2\u20134.5), Caucasian race (OR = 2.9, CI = 2.6\u20134.4), and distant SEER stage (OR = 2.5, CI = 1.1\u20133.2) were all linked with increased mortality (p &lt; 0.001). Conclusion: An extremely rare and aggressive peritoneal tumor, PPM may be difficult to identify at the time of diagnosis. Radiation therapy likely to have a limited function in the treatment of this condition, with surgery and chemotherapy being the primary choices. All PPM patients should be enrolled in a nationwide registry to improve our understanding of the pathogenesis and identify factors affecting survival.<\/jats:p>","DOI":"10.3390\/cancers14040942","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T20:26:42Z","timestamp":1644870402000},"page":"942","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Incidence, Survival Analysis and Future Perspective of Primary Peritoneal Mesothelioma (PPM): A Population-Based Study from SEER Database"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9435-9625","authenticated-orcid":false,"given":"Asad","family":"Ullah","sequence":"first","affiliation":[{"name":"Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9992-6051","authenticated-orcid":false,"given":"Abdul","family":"Waheed","sequence":"additional","affiliation":[{"name":"Department of Surgery, San Joaquin General Hospital, French Camp, CA 95231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaffar","family":"Khan","sequence":"additional","affiliation":[{"name":"Department of Pathology, Indiana University School of Medicine, Indianapolis, IN 46202, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankita","family":"Mishra","sequence":"additional","affiliation":[{"name":"Department of Surgery, Brandon Regional Hospital, Brandon, FL 33511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bisma","family":"Tareen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Bolan Medical College, Quetta 87300, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor","family":"Nama","sequence":"additional","affiliation":[{"name":"Department of Medicine, Bolan Medical College, Quetta 87300, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabin Raj","family":"Karki","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Saleem","family":"Panezai","sequence":"additional","affiliation":[{"name":"Department of Medicine, Bolan Medical College, Quetta 87300, Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Velasquez","family":"Zarate","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"White","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick D.","family":"Cason","sequence":"additional","affiliation":[{"name":"Department of Surgery, San Joaquin General Hospital, French Camp, CA 95231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Matolo","sequence":"additional","affiliation":[{"name":"Department of Surgery, San Joaquin General Hospital, French Camp, CA 95231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhasis","family":"Misra","sequence":"additional","affiliation":[{"name":"Department of Surgery, Brandon Regional Hospital, Brandon, FL 33511, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagla Abdel","family":"Karim","sequence":"additional","affiliation":[{"name":"Georgia Cancer Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,2,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pouliquen, D.L., and Kopecka, J. (2021). Malignant Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13143447"},{"key":"ref_2","first-page":"383","article-title":"Mesotelioma peritoneal maligno: Dificuldades diagn\u00f3sticas e terap\u00eauticas","volume":"15","author":"Cunha","year":"2002","journal-title":"Acta Med. Port."},{"key":"ref_3","first-page":"e3906","article-title":"Malignant Peritoneal Mesothelioma Mimicking Recurrent Diverticulitis","volume":"11","author":"Gonzaga","year":"2019","journal-title":"Cureus"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.ctrv.2011.10.006","article-title":"Diffuse malignant peritoneal mesothelioma\u2014An update on treatment","volume":"38","author":"Mirarabshahii","year":"2012","journal-title":"Cancer Treat. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Dipper, A., Maskell, N., and Bibby, A. (2021). Ancillary Diagnostic Investigations in Malignant Pleural Mesothelioma. Cancers, 13.","DOI":"10.3390\/cancers13133291"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1001\/archsurg.1990.01410230071012","article-title":"Primary Malignant Peritoneal Mesothelioma: A report of seven cases and a review of the literature","volume":"125","author":"Asensio","year":"1990","journal-title":"Arch. Surg."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"915","DOI":"10.21037\/jgo.2017.08.01","article-title":"Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: A review","volume":"8","author":"Mehta","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_8","first-page":"52","article-title":"Pathologic diagnosis of malignant mesothelioma: Chronological prospect and advent of recommendations and guidelines","volume":"51","author":"Valeria","year":"2015","journal-title":"Ann. Dell\u2019istituto Super. Sanit\u00e0"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s13193-016-0539-8","article-title":"Role of Imaging in Peritoneal Surface Malignancies","volume":"7","author":"Krishnamurthy","year":"2016","journal-title":"Indian J. Surg. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.21037\/atm.2017.03.96","article-title":"Malignant peritoneal mesothelioma: A review","volume":"5","author":"Kim","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_11","first-page":"333","article-title":"Treatment of Malignant Peritoneal Mesothelioma","volume":"32","year":"2019","journal-title":"Klin. Onkol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"13257","DOI":"10.1038\/s41598-020-70044-8","article-title":"Prognostic role of radiological peritoneal cancer index in malignant peritoneal mesothelioma: National cohort study","volume":"10","author":"Salo","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.canep.2019.03.014","article-title":"Incidence and survival of peritoneal malignant mesothelioma between 1989 and 2015: A population-based study","volume":"60","author":"Bouvier","year":"2019","journal-title":"Cancer Epidemiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10552-009-9328-9","article-title":"Pleural and peritoneal mesotheliomas in SEER: Age effects and temporal trends, 1973\u20132005","volume":"20","author":"Moolgavkar","year":"2009","journal-title":"Cancer Causes Control"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4560","DOI":"10.1200\/JCO.2003.04.150","article-title":"Analysis of Factors Associated with Outcome in Patients with Malignant Peritoneal Mesothelioma Undergoing Surgical Debulking and Intraperitoneal Chemotherapy","volume":"21","author":"Feldman","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/1097-0142(19840901)54:5<951::AID-CNCR2820540536>3.0.CO;2-A","article-title":"Non-asbestos-related malignant mesothelioma. A review","volume":"54","author":"Peterson","year":"1984","journal-title":"Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.5588\/ijtld.19.0645","article-title":"Asbestos-related diseases","volume":"24","author":"Musk","year":"2020","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"ref_18","first-page":"1005","article-title":"Chemoprevention of asbestos-linked cancers: A systematic review","volume":"32","author":"Neri","year":"2012","journal-title":"Anticancer Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamaoncol.2017.2918","article-title":"Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma","volume":"4","author":"Hung","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1245\/s10434-006-9192-8","article-title":"Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion","volume":"14","author":"Baratti","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13073-019-0620-3","article-title":"BAP1 haploinsufficiency predicts a distinct immunogenic class of malignant peritoneal mesothelioma","volume":"11","author":"Shrestha","year":"2019","journal-title":"Genome Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s11864-008-0072-2","article-title":"Peritoneal Mesothelioma","volume":"9","author":"Hesdorffer","year":"2008","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.pathol.2016.11.012","article-title":"Metastatic primary peritoneal malignant mesothelioma mimicking primary diffuse gastric carcinoma: A rare encounter in gastric biopsy","volume":"49","author":"Yang","year":"2017","journal-title":"Pathology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/annonc\/mdv101","article-title":"Searching for targets for the systemic therapy of mesothelioma","volume":"26","author":"Stahel","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.21037\/tlcr.2019.11.29","article-title":"Application of immunohistochemistry in diagnosis and management of malignant mesothelioma","volume":"9","author":"Chapel","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/modpathol.2016.188","article-title":"Genomic profiling of malignant peritoneal mesothelioma reveals recurrent alterations in epigenetic regulatory genes BAP1, SETD2, and DDX3X","volume":"30","author":"Joseph","year":"2017","journal-title":"Mod. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/978-1-4613-1245-1_17","article-title":"Peritoneal mesothelioma: Treatment approach based on natural history","volume":"81","author":"Averbach","year":"1996","journal-title":"Cancer Treat. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"511","DOI":"10.5505\/aot.2020.71931","article-title":"Multimodality Treatment for Peritoneal Mesothelioma: A Single Center Experience","volume":"53","author":"Aksel","year":"2020","journal-title":"Acta Oncol. Turc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"839","DOI":"10.21873\/anticanres.13183","article-title":"Malignant Peritoneal Mesothelioma: Treatment Options and Survival","volume":"39","author":"Salo","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00384-014-2029-1","article-title":"Advances in malignant peritoneal mesothelioma","volume":"30","author":"Cao","year":"2015","journal-title":"Int. J. Colorectal Dis."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0360-3016(82)90379-0","article-title":"Radiation therapy in the management of patients with mesothelioma","volume":"8","author":"Gordon","year":"1982","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_33","first-page":"302","article-title":"A case of peritoneal malignant mesothelioma following radiation therapy for cervical cancer","volume":"8","author":"Yano","year":"2018","journal-title":"Mol. Clin. Oncol."},{"key":"ref_34","first-page":"659","article-title":"Malignant peritoneal mesothelioma: Clinical aspects, and therapeutic perspectives","volume":"31","author":"Boussios","year":"2018","journal-title":"Ann. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(17)30446-1","article-title":"Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): A multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial","volume":"18","author":"Maio","year":"2017","journal-title":"Lancet Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/942\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:19:13Z","timestamp":1760134753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/4\/942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,14]]},"references-count":35,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,2]]}},"alternative-id":["cancers14040942"],"URL":"https:\/\/doi.org\/10.3390\/cancers14040942","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,14]]}}}